ReviewNaunyn-Schmiedeberg's archives of pharmacology2026
Sex differences in coronary artery disease.
Review in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myocardial infarction is the leading cause of death worldwide in men and in women. Nevertheless, cardiovascular diseases in women are still understudied, underdiagnosed and undertreated leading to poor outcomes and higher mortality rates. Important sex differences exist in coronary artery disease with a higher symptom burden, delayed presentation and treatment of women in the emergency department and more non-obstructive coronary artery disease on angiogram. Sex hormones influence hemostasis and platelet function, and women suffer more from major bleeding complications after coronary interventions. Moreover, cholesterol levels increase with age particularly in women and sex hormones might play an important role in the development and progression of atherosclerosis with an increasing cardiovascular risk for women after menopause. Women also have other unique sex-specific risk factors such as hypertensive disorders of pregnancy that are contributing to an increased risk of myocardial infarction. Therefore, pharmacological therapies regarding primary or secondary prevention of coronary artery disease need to address sex differences to improve female outcome in the future. This review highlights these differences and specific risk factors in women to consider in pharmacological management of coronary artery disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.